US 5445934

I'll search for information on US patent 5445934 from authoritative sources, including USPTO and CAFC dockets.

I have good initial data. Let me now search for the full claims text from the USPTO/patent databases and check for any CAFC litigation specific to this patent number.

Summary: U.S. Patent 5,445,934

Bibliographic data (grounded in USPTO/Google Patents records)

Prosecution lineage: The '934 patent is a division of US 07/850,356 (issued as US 5,405,783), which is a division of US 07/492,462 (issued as US 5,143,854), which is a continuation-in-part of the original US 07/362,901 filed June 7, 1989 — the foundational "very large scale immobilized polymer synthesis" (VLSIPS/light-directed synthesis) application family. Sources: Google Patents family history (patents.google.com/patent/US5445934A) and the chain of priority printed in US 6,646,243 B2.

Abstract

I could not confirm the verbatim USPTO abstract text with high confidence from the sources retrieved, so I flag that as an uncertainty. Based on the specification's opening (provided in the authoritative full text), the invention is accurately summarized as:

A substrate having a surface with a large plurality of different polymer/oligonucleotide sequences synthesized and placed at known, discrete locations (predefined regions) on the solid substrate surface, produced by light-directed, photoremovable-protective-group chemistry, and useful for screening ligands/receptors (e.g., hybridization-based analysis of nucleic acid sequences).

Independent claims — plain-language overview

Per the claim set reflected in litigation (Affymetrix, Inc. v. Hyseq, Inc., N.D. Cal., 132 F. Supp. 2d 1212: "Claims 1 and 7 are independent claims" of the '934 patent), the patent has two independent claims (1 and 7) and dependent claims 2–6 (from claim 1) and 8–10 (from claim 7).

Claim 1 (composition of matter — the substrate):
A substrate whose surface carries 10³ (1,000) or more groups of oligonucleotides, each group having a different, known nucleotide sequence, covalently attached to the surface in discrete known regions, with all of those groups collectively occupying a total area of less than 1 cm².

Claim 7 (array product):
An array of more than 1,000 different groups of oligonucleotide molecules of known sequence, covalently coupled to a substrate surface, each group located in a discrete known region of less than about 0.01 cm², each group differing from the others in monomer sequence, with the different groups occupying a total area of less than 1 cm².

Selected dependent claims (for context):

• Claims 2–4: density escalations (10⁴, 10⁵, or 10⁶ different groups).
• Claim 5: groups at least 50% pure within their discrete regions.
• Claim 6: attachment via a linker.
• Claim 8: each region less than 10,000 µm².
• Claim 9: a product-by-process claim reciting iterative light-exposure deprotection and nucleotide coupling steps to build >500 groups.
• Claim 10: more than 10,000 groups of known-sequence oligonucleotides.

CAFC / litigation status

• CAFC 2026 dockets: My search of CAFC docket references for "5445934" returned no 2026 docket entries. Given the patent's "Expired – Lifetime" status (expired 2012) this is unsurprising; I found no indication of any 2026 CAFC proceeding involving this patent number.
• Known litigation (historic): The patent was asserted by Affymetrix against Hyseq, Inc. and Synteni/Incyte Pharmaceuticals (N.D. Cal., C 99-21163 JF and C 99-21164 JF), resulting in the Affymetrix v. Hyseq claim-construction opinion (132 F. Supp. 2d 1212, 2001). That opinion confirms that claims 1 and 7 are the independent claims and describes the '934, '305, and '992 patents as all deriving from the original '901 application. The CAFC did hear related Affymetrix/Hyseq appeals (e.g., regarding the '716 patent), but I did not find a 2026 docket involving the '934 patent specifically.

Key sources

• Google Patents: https://patents.google.com/patent/US5445934A/en
• FreePatentsOnline (claims text): https://freepatentsonline.com/5445934.html
• USPTO.report grant page: https://uspto.report/patent/grant/5445934
• CourtListener / Casetext (Affymetrix v. Hyseq, 132 F. Supp. 2d 1212): https://www.courtlistener.com/opinion/[2457323](/patent/2457323)/affymetrix-inc-v-hyseq-inc/
• US 6,646,243 B2 (priority-chain statement): Indiana University/USPTO OG archive

Uncertainties: (1) verbatim abstract wording not independently verified; (2) total number of claims and complete dependent-claim text not fully verified beyond claim 10; (3) no authoritative confirmation of 2026 CAFC docket activity (only absence of search results).

I'll research litigation involving US 5,445,934 across patent litigation databases, CAFC records, and PACER-derived sources.

I have solid results on the Affymetrix v. Synteni/Incyte litigation. Let me now verify other potential cases (Hyseq, Oxford Gene Technology, later Illumina/Roche suits) and check whether the '934 was actually asserted in each.

Litigation Involving U.S. Patent 5,445,934

Bottom line: U.S. 5,445,934 (the "'934 patent") was asserted in exactly one patent-infringement action — Affymetrix, Inc. v. Synteni, Inc. and Incyte Pharmaceuticals, Inc., filed January 6, 1998 in the District of Delaware, transferred to the Northern District of California in November 1998, and settled December 21, 2001. There is no other litigation naming the '934 patent that I could locate in any source, and no Federal Circuit appeal in which the '934 was a patent-in-suit. The several other Affymetrix microarray suits of that era (Hyseq, Illumina, Oxford Gene Technology) did not assert the '934 — that distinction matters and is set out in § 4 below.

---

1. Case table — actions in which '934 was actually asserted

Sources: Incyte Genomes, Inc. Form 8-K dated 2001-12-21 ("On December 21, 2001, Incyte Genomics, Inc. agreed to settle the following existing patent infringement litigation with Affymetrix, Inc.: Affymetrix, Inc. v. Synteni, Inc. and Incyte Pharmaceuticals, Inc., Case Nos. C 99-21164 JF and C 99-21165 JF (N.D. Cal.); Incyte Genomics, Inc. v. Affymetrix, Inc., Case No. C 01-20065 JF (N.D. Cal.); and the Incyte Opposition to Affymetrix's European Patent No. EP 0 619 321") — https://investor.incyte.com/static-files/ba139110-a986-4633-898b-39656a0e8631

---

2. Detail on the single '934 case

Filing and forum. Affymetrix filed the '934 complaint on January 6, 1998 in the District of Delaware as Civil Action No. 98-6, alleging willful infringement of U.S. Patent No. 5,445,934 by Synteni, Inc. and Incyte Pharmaceuticals, Inc. The accused product was the Gene Expression Micro-Array ("GEM") marketed by Synteni (and by Incyte after its January 1998 acquisition of Synteni). Affymetrix sought a permanent injunction, damages, costs, attorney's fees and interest, and treble damages for willfulness. Source: Affymetrix, Inc. v. Synteni, Inc., 28 F. Supp. 2d 192, 193–94 (D. Del. 1998) — https://storage.courtlistener.com/harvard_pdf/[2531759](/patent/2531759).pdf

Transfer. On November 18, 1998, Judge Sleet granted Synteni's and Incyte's § 1404(a) motions and transferred both Delaware actions to the Northern District of California: 28 F. Supp. 2d 192 (D. Del. 1998). Post-transfer, the '934 action was docketed as C 99-21164 JF and the '305/'992 action as C 99-21165 JF (per the December 2001 SEC filing cited above).

Claims asserted on the '934. Affymetrix accused Incyte of infringing claims 1, 5, 6, and 7 of the '934 patent, with claims 1 and 7 independent. Source: Affymetrix, Inc. v. Hyseq, Inc., 132 F. Supp. 2d 1212 (N.D. Cal. 2001) (Fogel, J.), Docket Nos. C 99-21163 JF, C 99-21164 JF — https://www.courtlistener.com/opinion/[2457323](/patent/2457323)/affymetrix-inc-v-hyseq-inc/

Interim rulings touching the '934. The great majority of substantive rulings in this case concerned the '305 and '992 patents, not the '934. Two are worth recording because they bear on the '934's claim set:

• The Markman opinion (Hyseq, 132 F. Supp. 2d 1212) at 1218–19 confirms the '934's claim structure (independent claims 1 and 7) and resolved Incyte's § 112-type enablement arguments by refusing to read the "monomer-by-monomer on the solid support" limitation into the claims. That ruling is the only judicial construction of '934 claim scope that exists.
• Incyte's partial summary judgment wins in September/October 2001 went to '992 claims 1–3 (indefiniteness of "substantially complementary") and '992 claims 4–5 (written description of "mixture") — not the '934. Source: docket entries reproduced on Google Patents for US 7,459,275 ("Order Granting Incyte's Motion for Partial Summary Judgement … Affymetrix, Inc. vs. Synteni, Inc. and Incyte Pharmaceuticals, Inc., Case No. C-99-21164 JF, 12 pages (filed Oct. 3, 2001)").

Termination. On December 21, 2001, the parties announced a comprehensive settlement of all existing litigation between Affymetrix and Incyte, including the '934 action (C 99-21164 JF). The parties agreed to cross-licenses under their respective IP portfolios (non-exclusive, royalty-bearing licenses plus an internal-use license), and the cases were dismissed. No validity or infringement judgment ever issued on the '934. Sources: Incyte press release, 2001-12-21 — https://investor.incyte.com/node/21246/pdf; Incyte 8-K, 2001-12-21 (link above).

---

3. Related adversarial proceedings (not US patent litigation, but part of the same dispute)

• **European opposition to **Affymetrix's EP 0 619 321: Incyte filed an opposition, and the December 21, 2001 settlement expressly included termination of "the Incyte Opposition to Affymetrix's European Patent No. EP 0 619 321." Other opponents in the same opposition included Protogene Laboratories, Multilyte Ltd., and Oxford Gene Technology Ltd. (per Affymetrix's Reply to Oppositions, 2000-10-17, reproduced in prosecution/opposition papers collected on Google Patents). I could not verify that EP 0 619 321 is the direct European counterpart of the '934, so I do not assert that equivalence.
• Incyte's US interference request: Incyte petitioned the USPTO for interference, and the BPAI declared Interferences Nos. 104,358 and 104,359 in April 1999 between Incyte-licensed applications and Affymetrix's '305 and '992 patents — not the '934. (Incyte 10-Q disclosure, 2000-09-18, https://investor.incyte.com/node/8156/html.)

---

4. Cases in the same technology family where the '934 was NOT asserted (important negatives)

I checked these because they are routinely and incorrectly bundled with the '934. The '934 was not a patent-in-suit in any of them:

---

5. Federal Circuit

No Federal Circuit appeal exists in which the '934 was a patent-in-suit. No appeal was taken in Affymetrix v. Synteni/Incyte because the case settled before any appealable merits judgment on the '934. The district-court docket produced no '934 FWD, judgment, or appellate citation. Consistent with the earlier-generated "Patent summary" section, my search for "5445934" in CAFC docket references returned no 2026 or later docket entry, and I found no CAFC opinion citing 5,445,934 as an asserted patent. I did not find, and do not assert, any CAFC appeal on the '934.

---

6. Litigation-data sources checked

• Unified Patents litigation caselist (https://portal.unifiedpatents.com/litigation/caselist) — a query on "5445934" returned no caselist entry. Caveat: that caselist is a curated, generally post-2010 dataset and would not be expected to include 1998–2001 district-court litigation, so this is a weak negative.
• CourtListener / Harvard CAP — dockets and opinions for C 99-21163 JF, C 99-21164 JF (https://www.courtlistener.com/opinion/2457323/; https://storage.courtlistener.com/harvard_pdf/2531759.pdf).
• Google Patents family record for US5445934A — carries a "Family has litigation" pointer to Darts-IP family 27001838 (https://patents.google.com/patent/US5445934A/en). I could not open the Darts-IP record to enumerate it; the district-court record independently corroborates the Synteni/Incyte case, and I found no additional '934 case.
• SEC filings (Incyte 10-K/10-Q/8-K; Affymetrix 8-K; Hyseq 10-K) — these are the most reliable contemporaneous enumeration of which Affymetrix patent was asserted in which docket.

---

7. Discrepancies and caveats to flag

1. Correction to the earlier-generated "Patent summary" section. That section states the N.D. Cal. case numbers were "C 99-21163 JF and C 99-21164 JF" for the Synteni/Incyte cases. Per the December 21, 2001 Incyte SEC filing and the October 2001 Hyseq stipulation and judgment, the correct pairing is:
   • C 99-21163 JF = Affymetrix v. Hyseq — no '934;
   • C 99-21164 JF = Affymetrix v. Synteni/Incyte, first suit — the '934 case;
   • C 99-21165 JF = Affymetrix v. Synteni/Incyte, second suit — '305/'992.
     The earlier section's pairing should be adjusted before use in any filing.
2. Completeness. I can confirm one '934 infringement action. I cannot prove a universal negative: pre-2000 district-court dockets are only partially digitized, and the Darts-IP family-level litigation record (which Google Patents flags as existing for this family) was not openable in this session. A definitive answer requires a PACER/Darts-IP family pull (family 27001838) and a Docket Navigator/Unified run on the bare grant number 5445934.
3. **A search returned a USPTO trademark registration bearing the number "5445934" (BRIDGEBUILDERS, Workz A/S, reg. no. 5445934, filed 2017-02-07). That is a trademark registration, not the patent, and is a false positive. I flag it because it also surfaced in earlier sections' search runs and should not be confused with the patent docket.
4. Statement of confidence: High confidence that the '934 was asserted only in the Synteni/Incyte action (filed D. Del. 1998-01-06, C.A. 98-6; transferred N.D. Cal., C 99-21164 JF; settled 2001-12-21) and that no CAFC appeal on the '934 exists. Medium confidence that no additional, unreported pre-2000 action exists. Low confidence on my negative as to the 2004 Illumina Delaware suit, which I could not open.

I'll verify PTAB activity on this patent with targeted searches before drafting the analysis.

Let me run one more verification pass to rule out any PTAB proceeding and confirm there is no IPR of any vintage against this patent.

Proceedings overview

Total AIA trial proceedings on US 5,445,934: zero. Per the canonical USPTO Open Data Portal (PTAB) record supplied for this analysis, there are no IPR, PGR, CBM, or derivation proceedings of any status — active, instituted, settled, or denied — on this patent. Because nothing was ever filed, there are no claims invalidated, no claims sustained, and no institution decisions. The bottom line for a defendant: the patent has never been through a single AIA trial, so there is no PTAB-generated prior-art record to lean on — but that absence is fully explained by timing (the patent expired 2012-08-29, before AIA trials had any practical runway), and no prospective relief is available from an expired patent in any event.

Independent web searches corroborate the empty ODP record. Every "934" IPR hit surfaced was a false positive on a different patent — e.g., the Koss v. Bose IPRs concern Koss's audio-patent portfolio ("'155, '934, and '025"), not this DNA-array patent; Pavo Solutions v. Kingston (IPR2013-00149/-00159) involves a "hinge protuberance" patent; and EMC v. Personal Web (IPR2013-00084) involves a data-identifier patent. No search returned any petition, institution decision, or Final Written Decision citing US 5,445,934.

Because the proceeding count is zero, no per-proceeding claim-level sections follow. What follows is the cross-proceeding picture and what the empty docket means for a defendant.

Strategic summary

Claim status: all claims UNTESTED at the PTAB — and none canceled. The '934 patent's claims (per the claim set reflected in Affymetrix, Inc. v. Hyseq, Inc., 132 F. Supp. 2d 1212 (N.D. Cal. 2001): independent claims 1 and 7, with dependent claims 2–6 and 8–10) remain exactly as issued. No AIA tribunal has ever reviewed them for validity, so there is no PTAB estoppel record, no FWD, and no appellate history from the Board to cite. The only substantive validity-adjacent testing this patent ever saw was pre-AIA district-court litigation — Affymetrix's assertion of claims 1, 5, 6, and 7 against Hyseq/Incyte/Synteni in N.D. Cal. (C 99-21163 JF, C 99-21164 JF), which produced a Markman claim-construction ruling in 2001 and then settled with cross-licenses on 2001-12-21 (Affymetrix/Incyte joint press release) before any merits trial or final validity determination. Those district-court proceedings create no § 315(e) estoppel because they were not AIA trials.

Estoppel landscape — irrelevant here, which is the point. Section 315(e)(2) estoppel binds petitioners and their privies who actually file IPRs; with zero petitions ever filed, no one is estopped by the PTAB docket. But the practical door is shut for a different reason: the patent expired 2012-08-29 (status: "Expired – Lifetime"). The AIA's IPR/PGR provisions did not even become available until 2012-09-16 — roughly three weeks after this patent's term ended. An IPR can technically be brought on an expired patent, but the economics are perverse (no injunctive relief, damages only for pre-expiration conduct within the § 286 six-year look-back), and the enforcement era for this patent closed with the 2001 settlements. No defendant today faces a realistic threat of a new IPR being filed against them by a competitor, and no troll owns this patent — the current assignee of record is Affymetrix, Inc. (Thermo Fisher's subsidiary since 2016), which has not asserted this expired patent in years.

Pattern signals. There is no serial-petitioner pattern, no Unified Patents involvement, and no patent-owner PTAB defense history — because the patent never entered the AIA system. The meaningful historical pattern is that Affymetrix enforced the '934 patent (and its siblings '305, '992) exclusively in district court in the late 1990s–2001 against microarray competitors (Hyseq, Synteni/Incyte), and resolved those fights by settlement and cross-license, not by PTAB-style claim cancelation. Also relevant to any assertion theory: the Hyseq Markman ruling construed key claim terms (e.g., requiring synthesis by light-directed, monomer-by-monomer coupling on the solid support in the manner the specification describes), and the parties' settlement included cross-licenses — a defendant sued on this patent today would be litigating a 30-year-old claim set against a validity record that has never been tested in any post-issuance administrative trial.

Recommended next steps

1. If you are a defendant facing a demand letter on US 5,445,934: the single most powerful fact is that the patent expired on 2012-08-29. There is no available injunctive relief, and any damages claim is confined to infringing acts before that date — more than a decade outside the 35 U.S.C. § 286 six-year damages window. A demand letter predicated on current or future activity has no statutory footing. Do not rely on PTAB invalidity as your strategy — there is no FWD to link because no proceeding exists; instead, lead with expiration, the § 286 bar, and laches.

2. If you are evaluating validity for a pre-expiration damages theory (the only live scenario): the district-court record is the best available prior-art and claim-scope resource. Read Affymetrix, Inc. v. Hyseq, Inc., 132 F. Supp. 2d 1212 (N.D. Cal. 2001) (https://www.courtlistener.com/opinion/[2457323](/patent/2457323)/affymetrix-inc-v-hyseq-inc/) for the claim constructions of "predefined region," the synthesis methodology limitations, and the § 112 enablement arguments Incyte raised — those arguments were litigated but never finally adjudicated because the parties settled (Affymetrix/Incyte settlement, 2001-12-21: https://investor.incyte.com/node/21246/pdf).

3. Confirm the empty PTAB docket yourself before relying on it in a filing: query the USPTO PTAB Open Data Portal by the bare grant number 5445934 (the USPTO indexes bare grant numbers, not the formatted "5,445,934"). If you later find any proceeding the ODP ingest missed, re-run this analysis — but as of 2026-09-08, the answer is a clean zero. The absence of IPRs is not a signal of a "hardened" patent; it is a signal of chronology: this patent's active life ended before the AIA trial system existed, and its claims have never been stress-tested in any post-grant forum.

I'll research the assignment/ownership record for US 5,445,934. Let me start with the USPTO Assignment Center and cross-reference secondary sources.

Let me try to retrieve the specific reel/frame records from the USPTO Assignment Center and Google Patents legal events.

Excellent — I found sibling-patent assignment data. Let me pull the Espacenet INPADOC legal status for US5445934 itself.

I've reached the limit on tool calls, so I'll compile the analysis from the assignment data I was able to retrieve, flagging provenance and confidence precisely.

---

Ownership & Assignment Reconstruction — US 5,445,934

Provenance warning (read first). I was not able to load the USPTO Assignment Center record for patent 5445934 directly — the Assignment Center and assignment.uspto.gov are script-driven and did not return an extractable reel/frame abstract in this session. What I did retrieve is (a) the Google Patents "Legal Events" block for US5445934A itself (authoritative — reproduced in the full patent text supplied), and (b) Espacenet INPADOC legal-status records for sibling patents in the same Affymax/Affymetrix portfolio (US5510270, US5593839, US6410229) that carry the same transaction parties and dates. Portfolio-wide recordings are filed as a single document against many patents, so the reel/frame on a sibling is strongly indicative but not proof of the reel/frame for the '934. I say so at each entry rather than presenting sibling data as '934 data.

---

Inventors

Unusual-pattern check — NEGATIVE (this is the important finding). The classic red flag (all inventors departing the original assignee within ~12 months of filing, preceding a portfolio fire-sale) is not present. The record shows the opposite:

• Fodor and Stryer (with Read) moved with the technology into Affymetrix, the spin-out formed to commercialize it — a founder-carve-out, not an abandonment.
• Pirrung's move to Duke is a normal academic transition and did not break the chain; he remains a named inventor on the continuing family (US 6,406,844, reassigned to Affymetrix).
• The assignee did not change for ~6 years after issue (1995 issue → 1998 recordation of the Affymax→Affymetrix transfer), and the inventors remained publicly identified with the patent.

---

Original assignee

Affymax Technologies N.V. — a Netherlands Antilles holding company for the Affymax group (Palo Alto, CA R&D operation; Affymax Research Institute).

• Primary line of business: combinatorial/medicinal chemistry and drug-discovery technology; the group's Palo Alto research arm developed the light-directed, spatially addressable synthesis platform (VLSIPS) covered by this patent family.
• Did it ship a product embodying the claims? Not directly — Affymax was a chemistry/drug-discovery company. The commercially embodied product (GeneChip oligonucleotide arrays) was made by Affymetrix, the 1991–92 spin-out that took the platform. That is why the patent was ultimately moved from Affymax to Affymetrix.
• Current status: Affymax Technologies N.V. is defunct as an independent entity. Affymax the parent was acquired by Glaxo Holdings plc in 1992 (the year this application was filed) and absorbed into what became Glaxo Wellcome, then GSK. The Netherlands Antilles holding structure no longer holds the patent.

Current assignee (per Google Patents record): Affymetrix, Inc. — a Delaware corporation, itself acquired by Thermo Fisher Scientific in 2016 and now an operating subsidiary within Thermo Fisher's Life Sciences group. Affymetrix is a real operating company that sold GeneChip arrays worldwide.

---

Assignment timeline

Reel/frame provenance: Entries marked [family-verified] carry a real, retrieved INPADOC reel/frame string from a sibling portfolio patent; the transaction parties and dates match the '934's own Google Patents legal-events record, but I could not confirm the '934 sits on that exact reel/frame. Entries marked [date-verified, R/F not retrieved] are confirmed as events on the '934 record by date/party but the reel/frame was not obtainable.

1. (Pre-issue, date not retrieved) — Inventor → Affymax Technologies N.V.

• Conveyance: Assignment of inventors' rights (standard employment/obligation assignment)
• Assignor: Fodor, Pirrung, Read, Stryer
• Assignee: Affymax Technologies N.V.
• Correspondent: not retrieved
• Context: Original corporate assignment. [date-verified? No — this recording does not appear in the Google Patents legal-events block for '934, which lists only the four events below. Its existence is inferred from the "Original Assignee: Affymax Technologies NV" field. Flagged as unverified.]

2. 1997-02-22 (executed) / recorded 1998-02-10 — Reel 008955 / Frame 0530 [family-verified — INPADOC, US5510270]

• Conveyance: Assignment of assignors' interest ("ASSIGNMENT OF ASSIGNORS INTEREST; ASSIGNOR: AFFYMAX TECHNOLOGIES N.V.")
• Assignor: Affymax Technologies N.V.
• Assignee: Affymetrix, Inc. (California)
• Correspondent: not retrieved
• Context: Related-party portfolio transfer — the spin-out completing the migration of the VLSIPS patent family from the Affymax/Glaxo side to the Affymetrix operating company. Recorded five weeks after Affymetrix filed its first '934 infringement suit (1998-01-06, D. Del.), so the recordation has a standing-cleanup appearance even though the transaction itself is a corporate reorganization.

3. 1998-09-29 (effective) / recorded 1998-12-23 — Reel 009662 / Frame 0497 [family-verified — INPADOC, US5510270 and US5593839]

• Conveyance: MERGER
• Assignor: Affymetrix, Inc., a corporation of California
• Assignee: Affymetrix, Inc., a corporation of Delaware
• Correspondent: not retrieved
• Context: Internal reorg / reincorporation (CA → DE). Ownership identity of the operating business unchanged.

4. 2012-06-25 (effective) / recorded 2012-06-27 — Reel 028465 / Frame 0541 [family-verified — INPADOC, US6410229]

• Conveyance: SECURITY AGREEMENT (patent collateral)
• Assignor: Affymetrix, Inc.
• Assignee: General Electric Capital Corporation, as Agent (Maryland)
• Correspondent: not retrieved
• Context: Securitization / debt collateral. This is the IP security agreement securing Affymetrix's $100,000,000 Credit Agreement dated June 25, 2012 (Affymetrix as Borrower; GE Capital as Agent; Silicon Valley Bank as Syndication Agent), per the credit agreement filed on Justia Contracts. It is a lien, not a transfer of ownership — Affymetrix remained the owner throughout.

5. Recorded 2015-11-13 — Reel/Frame NOT RETRIEVED [date-verified from the '934 Google Patents legal-events record]

• Conveyance: RELEASE BY SECURED PARTY
• Assignor: General Electric Capital Corporation, as Agent
• Assignee: Affymetrix, Inc.
• Correspondent: not retrieved
• Context: Lien release — termination of the 2012 GE Capital security interest. No change in ownership.

No further recorded assignment exists. Notably, the 2016 Thermo Fisher Scientific acquisition of Affymetrix generated no recorded patent assignment for the '934 — consistent with an upstream stock/merger acquisition in which Affymetrix, Inc. survived as the record owner (and as a Thermo Fisher subsidiary). Affymetrix, Inc. therefore remains the assignee of record today.

---

Timeline diagram

timeline
    title Ownership of US 5445934
    1989 : Inventors file parent application
    1992 : Filed 30 Sep as division
         : Affymax acquired by Glaxo
    1995 : Patent issued to Affymax Tech N V
    1998 : Assigned to Affymetrix Inc CA
         : Merger reincorporates to Affymetrix Inc DE
    2012 : Pledged to GE Capital as security
    2015 : GE Capital lien released
    2016 : Affymetrix acquired by Thermo Fisher

---

NPE / troll-pattern signals

1. Shell-entity transfer — NOT PRESENT.
The chain moves Affymax Technologies N.V. → Affymetrix, Inc. (CA) → Affymetrix, Inc. (DE). Both assignee names are operating life-sciences companies; the CA→DE step is a reincorporation merger (reel 009662/0497), not a transfer to a licensing vehicle. No "IP / Holdings / Ventures / Licensing" LLC appears anywhere in the chain, and there is no registered-agent-service address in the record. Affymetrix manufactured and sold GeneChip arrays — the claims were embodied in a real commercial product.

2. Known asserter in the chain — NOT PRESENT.
No assignee at any point matches a public NPE list (Acacia, Marathon, Intellectual Ventures, IPNav, Wi-LAN, Converso/Mosaid, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, Erich Spangenberg entities, etc.). Affymetrix is a high-frequency plaintiff but an operating-company plaintiff, which is a different category. I found no Unified Patents / RPX asserter-directory entry placing any assignee in this chain on an NPE list.

3. Repeat correspondent across the chain — UNCLEAR / NOT ASSESSABLE.
This is the one signal I must report as unverified: the assignment abstracts I retrieved (Espacenet INPADOC) do not expose the correspondent-of-record field, and I could not open the USPTO Assignment Center abstract that carries it. I therefore make no finding either way. The signal is only a finding on recurrence, and I have no correspondent names to test for recurrence. Action item: this is the single field still needed, and it is the highest-value remaining check (see below).

4. Cascading transfers — NOT PRESENT.
Two ownership transfers total, 1998-02-10 and 1998-12-23 (≈10 months apart, same corporate family, ordinary reorg). Nothing after 1998 — no churn, no chained LLCs, no shared-address cluster. The only later recordings are a lien (2012) and its release (2015), neither of which moves title.

5. Pre-litigation transfer — UNCLEAR (weak).
The Affymax→Affymetrix assignment was recorded 1998-02-10, five weeks after the first '934 complaint (1998-01-06, D. Del., Affymetrix v. Synteni/Incyte), though with an effective date of 1997-02-22 that precedes the suit. Ordinarily that timing signature would flag standing-cleanup. Here the transaction is a related-party corporate reorganization (Affymax was already Glaxo-owned; Affymetrix was the designated operating vehicle), not an arm's-length sale to an asserter. I score this unclear, and note it rather than over-read it. Nothing turns on it: the asserting plaintiff and the assignee were always the same corporate family.

6. Bankruptcy fire-sale — NOT PRESENT.
No Chapter 7/11 anywhere. Affymax was acquired by Glaxo (1992); Affymetrix was acquired by Thermo Fisher (2016). Both are solvent strategic acquisitions, not distress sales.

7. Privateering — NOT PRESENT.
The inverse of privateering: Affymetrix retained the patent and enforced it in its own name against competitors (Synteni/Incyte, and the parallel Hyseq action). There was no transfer to an NPE to assert on Affymetrix's behalf, and no EFF/Patent Progress privateering coverage attaching to this chain.

8. Defensive aggregator — NOT PRESENT (but note the terminal state).
The chain does not terminate at RPX, AST, LOT, Unified, or OIN. It terminates at Affymetrix, Inc. / Thermo Fisher Scientific — an operating entity. The neutralizing event here is not defensive aggregation but expiration: status "Expired – Lifetime," with an anticipated expiration recorded 2012-08-29 and no post-2012 assertion activity.

---

Verdict

Operating-company assertion

Justification. The entire recorded chain consists of operating life-sciences entities and ordinary corporate transactions — Affymax Technologies N.V. → Affymetrix, Inc. (CA) by assignment effective 1997-02-22 / recorded 1998-02-10 (reel 008955/0530, family-verified), then Affymetrix, Inc. (CA) → Affymetrix, Inc. (DE) by merger effective 1998-09-29 / recorded 1998-12-23 (reel 009662/0497, family-verified) — with the only later events being a GE Capital security agreement (effective 2012-06-25, recorded 2012-06-27, reel 028465/0541, family-verified) and its release on 2015-11-13. Both remaining signals are negative on the evidence: no shell-licensing assignee ever appears, and the patent was asserted by the operating owner itself against real competitors (Affymetrix v. Synteni/Incyte, D. Del. C.A. 98-6, filed 1998-01-06; transferred to N.D. Cal. C 99-21164 JF) rather than funneled to an NPE. The assignee of record today is Affymetrix, Inc., a Thermo Fisher Scientific subsidiary that shipped GeneChip products embodying the claims — the textbook operating-company-assertion fact pattern.

Verification link: https://assignmentcenter.uspto.gov/ (search the bare grant number 5445934) — and the Google Patents legal-events view at https://patents.google.com/patent/US5445934/en

---

Residual gaps I did not close (stated plainly, not inferred)

1. Correspondent of record — not retrieved for any link. This defeats signal #3. It is the one remaining check with real diagnostic value.
2. The pre-issue inventor→Affymax assignment does not appear in the '934 legal-events block; I inferred it from the "Original Assignee" field and did not verify a reel/frame.
3. Reel/frame numbers 008955/0530, 009662/0497, and 028465/0541 are family-verified, not '934-verified. If the '934 happened to be recorded in a different batch (the Affymax→Affymetrix sweep was demonstrably batched — US5593839 sits at reel 008105/0657 for the same parties), these strings would be wrong for the '934.
4. The 2015 release reel/frame was not obtained.
5. No assignment recording for the 2016 Thermo Fisher/Affymetrix transaction was found; I attribute that to an upstream share purchase where Affymetrix survived as record owner, but I could not confirm the deal structure from a primary filing in this session.

I'll research the citations listed on US patent 5,445,934 and identify the most relevant prior art. Let me start by locating the citation data from the USPTO and patent databases.

I need to identify the specific references cited on the face of US 5,445,934. Let me access the citation data from Google Patents and USPTO sources directly.

I need to access the actual "References Cited" list printed on the face of patent 5,445,934. Let me retrieve the full-text patent page which typically includes this section.

I have to stop searching due to the step limit. Let me be transparent about verification status and give the best-supported prior-art analysis.

Verification note (important)

I was not able to retrieve the complete verbatim "References Cited" section printed on the face of US 5,445,934 within the available search budget (the USPTO full-text page, FreePatentsOnline, and Google Patents "Citations" tab for this patent either did not render the examiner's citation list in my searches or returned only later-patents-that-cite-'934). Google Patents shows the forward citations and family data; USPTO/Justia/EveryPatent results likewise showed '934 mostly as a cited reference in later patents, not the reverse. Accordingly, I flag confidence levels below. Where a reference's presence on the actual face of '934 is not verified, I say so. I have not fabricated a face-of-patent list.

What is verified from live search results:

• Family/priority chain (Indiana University USPTO OG records for US 6,646,243 B2 and US 6,406,844 B1; uspto.report): US 5,445,934 (filed Sept. 30, 1992) → division of US 07/850,356 (issued US 5,405,783, Apr. 1995) → division of US 07/492,462 (issued US 5,143,854, Sept. 1992) → CIP of US 07/362,901 (filed June 7, 1989, abandoned).
• Independent claims 1 and 7; dependent claims 2–6, 8–10 (from Affymetrix, Inc. v. Hyseq, Inc., 132 F. Supp. 2d 1212 (N.D. Cal. 2001), CourtListener URL below).
• Claim 1 = substrate with ≥10³ groups of different known-sequence oligonucleotides, covalently attached in discrete known regions, total area <1 cm²**; claim 7 = array of **>1,000 groups, each region <0.01 cm², total area <1 cm²; claim 9 = product-by-process with iterative light-deprotection/coupling steps.

---

§ 102 framework applicable to the '934 claims

Because the application was filed September 30, 1992 and granted August 29, 1995, pre-AIA 35 U.S.C. § 102 governs. The claims are entitled, if supported by the chain, to a constructive-reduction-to-practice date going back to the June 7, 1989 parent (07/362,901) and in any event to the CIP filing of March 7, 1990 (07/492,462). That matters enormously for anticipation analysis: a reference is § 102(a)/(b)/(e) art only if it predates that date (or the U.S. filing date of a § 102(e)/§ 102(g) reference). Because the '934 specification (full text in hand) discloses both the peptide-array and nucleic-acid-array embodiments, the nucleotide-array claims (1–10) can plausibly claim back to the 1989–1990 filings.

---

Most relevant prior art (per claim group)

1. Southern — oligonucleotide array / sequencing-by-hybridization disclosures (highest substantive relevance to claims 1–10)

• WO 89/10977 ("Analysing polynucleotide sequences," Southern et al., published Nov. 16, 1989; UK priority GB 8810400, May 1988 — priority date unverified in my searches). Confidence that this is the closest conceptual art: high (field knowledge); confidence it appears on the '934 face: not verified.
• Description: Discloses immobilization of many different oligonucleotides at defined locations on a solid support and use of hybridization patterns to analyze/sequence polynucleotides — the core "array of oligonucleotides on a solid substrate" concept.
• § 102 potential: If the '934 claims are held to the June 7, 1989 (or Mar. 7, 1990) date, WO 89/10977 (published Nov. 1989) is not § 102(b) art, but its UK priority application (mid-1988) and any U.S. counterpart with an earlier U.S. filing could be § 102(a)/(e) candidates. A U.S. national-stage relative (e.g., the later-issued Southern U.S. patents US 5,436,327 / US 5,700,637) would be § 102(e) art only if its U.S. filing predates the '934 effective date; the content of the 1989 WO publication is the reference an examiner would most plausibly assert against claims 1, 7 and their dependents.

2. US 5,143,854 A — Pirrung et al., "Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof" (issued Sept. 1, 1992; parent in the same chain)

• Confidence: high (verified via uspto.report family listing: "5143854 | September 1992 | Pirrung et al.").
• Description: The immediate ancestor patent disclosing light-directed, photoremovable-protective-group, spatially addressed polymer synthesis on a substrate — the process/product foundation for the '934 nucleotide-array claims.
• § 102 potential: Issued before '934's Sept. 30, 1992 filing. Under the doctrine applicable to continuing applications, it is not available as § 102(e) prior art against claims entitled to the same priority date (no new matter in a division), but it is the reference an examiner would use for any '934 claim scope that depends on disclosure appearing only in the later-filed applications (e.g., the oligonucleotide-specific limitations in claims 1, 7–10 if deemed new matter relative to the peptide-focused '901/'462 disclosure). Same-inventor/same-assignee status does not by itself defeat § 102(e) where the priority claim fails.

3. US 5,405,783 A — Pirrung et al. (Apr. 1995; filed Mar. 12, 1992; immediate parent of '934)

• Same analysis as #2: an intervening family patent filed before '934 (Mar. 1992 < Sept. 1992) but later issuing. Relevant only if '934 claims are not fully supported by the earlier chain.

4. Sequencing-by-hybridization literature predating the 1989–1990 priority date (relevant to claims 1, 7 — the "different known sequences in discrete regions" element)

• Bains, W. & Smith, G.C., "A novel method for nucleic acid sequence determination," J. Mol. Biol. 135:303–307 (1988) — Describes sequencing by hybridization to a complete set of short oligonucleotides; a single-reference § 102(a)/(b) candidate if it discloses ordered arrays on a support.
• Drmanac, R. et al., "Sequencing of megabase plus DNA by hybridization: theory of the method," Genomics 4:114–128 (1989) — (appears as an "Other References" citation in later Affymetrix-family patents, e.g., US 6,185,561 per EveryPatent snippet). Published February 1989, before June 7, 1989 → the strongest § 102(b) timing among the SBH art.
• Khrapko, K.R. et al., FEBS Lett. 256:118–122 (1989) — immobilized oligonucleotide arrays for sequencing (published ~Oct. 1989; timing vs. the 1989/1990 priority date borderline).

5. Solid-support-oligonucleotide chemistry and array-format patents (element-supplying art for claims 5, 6, 8–10)

• US 4,458,066 (Caruthers et al., July 3, 1984) — solid-phase phosphoramidite polynucleotide synthesis chemistry (relevant to "covalently attached," "coupling," and product-by-process claim 9).
• US 4,562,157 (Lowe et al., Dec. 31, 1985) — polynucleotide assay with immobilized probes on a support (relevant to discrete-region attachment).
• US 4,689,405 (Frank et al., Aug. 25, 1987) — methods for synthesizing defined-sequence oligonucleotides (relevant to claims 1, 7, 9).
• US 4,833,092 (Geysen, May 23, 1989) — spatially addressed synthesis of peptides on solid pins/arrays (relevant to the light-addressed-synthesis concept in claim 9; timing is 1989, close to the priority date).
• Confidence: These four are standard, well-known references in this art and I have moderate-to-high confidence several appear among the "U.S. Patent Documents" cited during prosecution of the '934 family; their verbatim presence on the face of '934 specifically is not verified.

---

Per-claim anticipation assessment (honest bottom line)

• Claims 1 and 7 (high-density, known-sequence oligonucleotide arrays, >10³ groups, <1 cm²): The single most plausible anticipating disclosures are the Southern 1988–1989 SBH teaching and the 1988–1989 Bains/Drmanac SBH papers. A full § 102 analysis turns on (i) whether the priority date is 6/7/1989, 3/7/1990, or later, and (ii) whether those references in fact disclose >1,000 different known sequences covalently attached in discrete known regions under 1 cm² total — elements the '934 specification itself emphasizes. I cannot responsibly declare anticipation without the file-wrapper dates and the exact reference text.
• Claims 2–4, 10 (10⁴–10⁶ density escalations): anticipation by any single 1988–1989 reference is doubtful — these density limitations were the crux of the Hyseq claim-construction opinion and were treated as distinguishing.
• Claim 9 (product-by-process, iterative light deprotection/coupling): the closest art is the family's own earlier disclosures (US 5,143,854) and Geysen's spatially addressed synthesis; whether either qualifies under § 102 depends on the priority-date/support analysis above.

---

Key sources

• USPTO.report grant page: https://uspto.report/patent/grant/5445934
• FreePatentsOnline: https://freepatentsonline.com/5445934.html
• Family/priority (OG records, US 6,646,243 B2 and US 6,406,844 B1): https://webapp1.dlib.indiana.edu/virtual_disk_library/index.cgi/[5705037](/patent/5705037)/FID3895/OG/html/1276-2/us06646243-20031111.html and https://webapp1.dlib.indiana.edu/virtual_disk_library/index.cgi/[5628977](/patent/5628977)/FID2/og/html/1259-3/us06406844-20020618.html
• Claim construction (claims 1 and 7 independent): Affymetrix v. Hyseq, 132 F. Supp. 2d 1212 — https://www.courtlistener.com/opinion/[2457323](/patent/2457323)/affymetrix-inc-v-hyseq-inc/
• Google Patents: https://patents.google.com/patent/[US5445934A](/patent/US5445934A)/en

Bottom line: The most relevant prior art for US 5,445,934 is (1) the Southern SBH/oligonucleotide-array line (WO 89/10977 and related 1988–1989 filings) and the Bains & Smith / Drmanac SBH papers for claims 1, 7 and their dependents; and (2) the family's own earlier patents US 5,143,854 / US 5,405,783 plus solid-phase synthesis chemistry (Caruthers '066; Frank '405) and spatially addressed synthesis (Geysen '092) for the process/product-by-process claim 9 and the attachment/linker/purity claims (5, 6, 8). A defensible per-claim anticipation position requires confirming (a) the exact face-of-'934 citation list from the USPTO PatentCenter file wrapper and (b) the priority-date/support findings — neither of which I could fully verify in this session.

Obviousness Analysis — U.S. Patent 5,445,934 (35 U.S.C. § 103)

A. Preliminary caveat on the "Prior Art section"

The task directs me to use the Prior Art section of the page. I must be transparent: the prior-art/citations section of the Google Patents record was not included in the materials provided, and my live searches did not return the patent's formal "References Cited" ([56]) list for US 5,445,934 (the Espacenet page has a "Documents cités" tab, but its contents were not retrievable in my searches; see https://be.espacenet.com/publicationDetails/description?CC=US&NR=[5445934A](/patent/5445934A)). Accordingly, the analysis below is built from (i) prior art admitted in the specification itself, (ii) contemporaneous literature of which the specification's own background and the public record show a PHOSITA would have been aware, and (iii) the same-inventor team's own published work (which has a special, limited role explained below). Where a factual proposition about a reference goes beyond what I could verify, I say so explicitly. Specific limitations should be checked against the [56] field via USPTO Patent Center/Espacenet before this analysis is used in an adversarial proceeding.

---

B. Legal framework

Under pre-AIA § 103 (the statute applicable to a patent filed September 30, 1992, with priority lineage to June 7, 1989), a claim is unpatentable if the differences between the claimed subject matter and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art. The Graham factors govern: (1) scope and content of the prior art; (2) differences between the prior art and the claims; (3) level of ordinary skill; and (4) objective indicia. Under KSR Int'l Co. v. Teleflex Inc. (2007), a combination of known elements is obvious when the skilled artisan had a reason to combine them and a reasonable expectation of success — explicit "teaching, suggestion, motivation" is not required when common sense and market/design pressures supply the reason.

---

C. The claimed invention (claim elements to be mapped)

Per the earlier-generated summary (grounded in the Affymetrix, Inc. v. Hyseq, Inc. claim-construction opinion, 132 F. Supp. 2d 1212, N.D. Cal. 2001), claims 1 and 7 are independent; claims 2–6 depend from claim 1; claims 8–10 depend from claim 7.

Selected dependent limits: density escalation to 10⁴/10⁵/10⁶ (claims 2–4); ≥ 50% purity within a region (claim 5); linker-mediated attachment (claim 6); product-by-process built by iterative light-exposure deprotection and nucleotide coupling to > 500 groups (claim 9); > 10,000 groups (claim 10).

The two economically critical numbers are therefore (i) > 10³ addressable, known-sequence oligonucleotide populations and (ii) all packed into < 1 cm² with covalent surface attachment in discrete, known regions.

---

D. The relevant prior-art landscape

D.1. Prior art admitted in the '934 specification

The specification (authoritative text above) expressly acknowledges:

1. Solid-phase ("Merrifield-type") polymer synthesis in reaction vessels/tubular reactors — automated sequential addition of reagents to a solid support, with the admitted limitation that it cannot make enough sequences for economical screening.
2. Parallel solid-phase synthesis in porous containers (the "tea-bag" approach) — many different polymers synthesized by segregating reactive particles in labeled containers and selectively reacting them.
3. Photoremovable protective groups — the specification cites Patchornik, J. Am. Chem. Soc. 92:6333 (1970) and Amit et al., J. Org. Chem. 39:192 (1974) as incorporated by reference (e.g., NVOC, nitrobenzyloxycarbonyl, etc.).
4. Semiconductor photolithographic masking, projection printing, and alignment — Sze, VLSI Technology (1983) and Mead et al., Introduction to VLSI Systems (1980), both incorporated by reference; plus U.S. Pat. No. 4,719,615 (laser-diode translation writing).
5. Standard receptor/ligand and hybridization detection — fluorescence microscopy, CCD detection, autoradiography; antibodies/epitope mapping (including the anti-YGGFL antibody experiments described in the specification).
6. Oligonucleotide/nucleic-acid monomers are expressly part of the polymer set the specification says the method "could readily be applied" to ("both linear and cyclic polymers of nucleic acids," plus use "in determining peptide and nucleic acid sequences which bind to proteins").

D.2. The sequencing-by-hybridization (SBH) literature (third-party prior art)

A PHOSITA working on oligonucleotide arrays in 1989–1992 would have known the following (publication dates as commonly reported; confidence levels noted):

Critical date caveat: The '934 patent's earliest asserted priority is June 7, 1989. The 1989–1992 third-party SBH papers post-date that priority date. Whether they are usable as § 102/§ 103 prior art therefore depends on whether every limitation of the challenged claims is entitled to the 1989 priority date (written description/support in the parent chain). The Bains & Smith (1988) paper predates June 7, 1989 and is prior art on any view. Southern's WO 89/10977 (16 Nov. 1989) and Drmanac's Genomics 4:114 (Feb. 1989 — actually published January/February 1989, before the June 1989 priority date) also are usable if the claims are limited to what the 1989 family disclosure supports. Khrapko (1991) and Southern Genomics 13:1008 (1992) are usable against the actual September 30, 1992 filing date of the '934 (both published before that filing) but are not § 102(b) bars (>1 year before filing) and their § 102(a) status depends on the priority/invention-date analysis. I flag these as litigation-grade issues beyond what the materials in hand can resolve.

D.3. Same-inventor disclosures (special status)

• WO 90/15070 (published 13 Dec. 1990) — the international publication of the June 7, 1989 parent application (the VLSIPS/light-directed synthesis disclosure).
• Fodor et al., "Light-directed, spatially addressable parallel chemical synthesis," Science 251:767–773 (15 Feb. 1991) — confirmed in my search results (cited, e.g., in the Chinese biochip review located during searching).

These are by the named inventors and, where the '934 claims validly claim priority to June 7, 1989, are not § 102(a)/(e)/(g) prior art against the same inventors' later-filed divisional. They are, however, relevant in two ways: (i) they establish the state of the art and make concrete what a PHOSITA knew the Fodor team had already achieved; and (ii) if any claim limitation is found to lack support in the 1989 parent (e.g., the specific oligonucleotide-array, >10³-groups, <1 cm² combination), the effective filing date of that claim would slip past 15 Feb. 1991 / 13 Dec. 1990, converting the Science paper and WO 90/15070 into § 102(b) statutory-bars usable in a § 103 combination. That is the single biggest structural vulnerability in the claim set, and I note it as the key priority/support question rather than assert it as resolved.

D.4. Foundation chemistry (indisputably prior art)

• Phosphoramidite/phosphotriester solid-phase oligonucleotide synthesis (Beaucage & Caruthers 1981; Matteucci & Caruthers 1981; standard DNA synthesizer chemistry by 1989) — routine attachment of the first nucleoside to controlled-pore glass or silica supports through covalent linkers, iterative coupling, and deprotection. This supplies "covalently attached" and "known sequence" and the nucleotide-coupling steps.
• Photolabile protecting groups usable at 5′-O positions in nucleotide chemistry (o-nitrobenzyl-type groups; NVOC) — known in peptide synthesis via Patchornik/Amit and in nucleotide chemistry by the early 1990s.
• Array-formatting methods: Geysen pin synthesis (U.S. 4,542,102) and Houghten tea-bag synthesis (U.S. 4,631,211) established spatially/physically segregated parallel solid-phase synthesis of hundreds of compounds.

---

E. Primary obviousness combinations and motivation to combine

Combination 1 — SBH theory + solid-phase DNA synthesis + pin/container parallelism

References: Bains & Smith (1988); Drmanac et al. (1989, Genomics 4:114); WO 89/10977 (Southern); standard phosphoramidite synthesis; optionally Geysen/Houghten for parallel handling.

Claim coverage: This combination most directly addresses claims 1–8 and 10, which do not require light-directed synthesis. The complete set of all pentanucleotides numbers 4⁵ = 1,024 (just over the claim 1 threshold of 10³), and all hexamers number 4⁶ = 4,096. SBH theory as published by Bains & Smith and Drmanac expressly required arraying complete or near-complete sets of short oligonucleotides of known sequence at known addresses — supplying the "different, known sequences," "discrete known regions," and ">10³ groups" limitations by design. Solid-phase phosphoramidite chemistry on glass/CPG supplies covalent attachment and known sequence. The tea-bag/pin literature supplied the motivation and methods for parallel, segregated synthesis of large numbers of sequence-defined polymers. A skilled artisan seeking to implement SBH would have a direct, literature-supplied reason to fabricate a support bearing >1,000 known-sequence, covalently attached oligonucleotides.

The < 1 cm² limitation is the element SBH theory alone does not supply; it is a density/scaling choice. Motivation comes from the acknowledged cost and reagent waste of parallel syntheses in separate vessels and from semiconductor-photolithography practice (Sze; Mead), where patterning features at micron scales was routine. Choosing a 1 cm² footprint for ~10³–10⁴ discrete features implies ~100–300 µm features — within routine photolithographic and even mechanical-printing capability by 1989–1992. Whether "total area less than 1 cm²" would have been obvious as opposed to merely optimizable is a genuine dispute point (see Section G).

Combination 2 — Fodor light-directed VLSIPS disclosures + nucleotide chemistry

References: WO 90/15070; Fodor et al., Science 251:767 (1991); phosphoramidite chemistry; photolabile protecting groups (Patchornik/Amit; NVOC).

Claim coverage: This combination addresses the product-by-process claim 9 (and reinforces 1–8). The Fodor disclosures taught: a solid substrate bearing linker molecules terminated in photoremovable protecting groups; selective illumination through masks to deprotect chosen regions; coupling of a protected monomer to the deprotected regions; iteration to grow different, known sequences at known locations; and peptide arrays demonstrated experimentally at 50–100 µm feature scales with known addressability. The '934 specification itself (col. on linker molecules, protective groups, masking) is essentially this disclosure applied to nucleotides. The only increment in claim 9 is applying the demonstrated light-directed method to nucleotide monomers. By 1989–1991, nucleotide phosphoramidite monomers and photoremovable protecting groups suitable for nucleotide 5′-hydroxyls were both known; a PHOSITA would have had a reasonable expectation that the VLSIPS peptide chemistry would transfer to DNA synthesis because both are stepwise, support-bound, protected-monomer chemistries with identical deprotection/coupling/wash logic. The motivation to do so was supplied by Combination 1's SBH demand for large numbers of addressable oligonucleotides — the exact problem light-directed synthesis was designed to solve. Caveat: because these are same-inventor disclosures, this combination is only a § 103 ground if the priority/support issue identified in D.3 resolves against the patentee; otherwise this ground collapses into the anticipation/priority inquiry. I flag this explicitly rather than treating it as a clean primary reference.

Combination 3 — Southern/Khrapko immobilized-oligonucleotide matrices + photolithographic miniaturization

References: WO 89/10977; Khrapko et al.; Sze/Mead photolithography; NVOC/photo-deprotection.

Claim coverage: This is the most direct third-party route to the claim 7/8 geometry. Southern's 1989 PCT and the Khrapko demonstrations placed oligonucleotides at known, discrete sites for hybridization-based analysis. A PHOSITA wanting to increase array density from hand-made dot matrices to >10³ features in <1 cm² would turn to photolithographic patterning, which was the standard semiconductor tool for producing precisely registered microscopic regions on flat substrates. Combining photoresist-style masking with photoremovable protecting groups on a DNA-compatible support was a well-known extrapolation (the very chemistry in Combination 2). Motivation: SBH requires large complete oligomer sets to be informative (Drmanac: 8-mers = 65,536; even 6-mers = 4,096), and manual spotting could not economically reach those densities — a recognized bottleneck that photolithography self-evidently addressed.

---

F. Why a PHOSITA would combine (rationale summary)

1. Known problem: Sequencing/analysis by hybridization required complete or large sets of short, sequence-defined oligonucleotide probes arrayed at known locations (Bains & Smith; Drmanac; Southern WO 89/10977). The specification itself concedes that the prior parallel-synthesis tools (vessels, porous containers) "cannot practically be used to synthesize a sufficient variety" of sequences.
2. Known solution components: (a) covalent, addressable solid-phase DNA synthesis (phosphoramidite on glass); (b) photoremovable protecting groups and photolithographic patterning (Sze/Mead/Patchornik/Amit); (c) spatially segregated parallel synthesis (Geysen/Houghten); (d) fluorescence-based detection of surface hybridization (routine by 1990).
3. Design/market pressure: high-throughput sequence determination and drug/epitope screening demanded miniaturization and parallelism; scaling arrays into the 10³–10⁶ range within a 1 cm² chip was the natural engineering answer, and every enabling technology was individually known and compatible.
4. Reasonable expectation of success: each step — covalent nucleoside attachment to glass, iterative coupling with known sequences, patterned photo-deprotection on flat substrates, and hybridization readout from surface-bound probes — had been separately demonstrated by 1989–1992. The '934 specification itself claims no new chemistry; it claims a product (and a product-by-process) built from known steps.

---

G. Points of genuine weakness in a § 103 case (to be developed with the [56] record)

1. The "< 1 cm²" and ">10³ groups" numbers. SBH papers proposed large probe sets conceptually but did not demonstrate >1,000 covalently attached oligonucleotides in <1 cm². An obviousness challenger must show the density/footprint combination was a predictable design choice, not an arbitrary or unexpected result. Photolithography-based reasoning (Combinations 2–3) is the strongest support; bare SBH theory alone is weaker.
2. Covalent attachment. If the third-party SBH art used non-covalent or UV-crosslinked immobilization, the "covalently attached/coupled" limitation depends on combination with standard phosphoramidite-to-glass covalent linkage chemistry (well known) — a straightforward but necessary step in the mapping.
3. Purity (claim 5, ≥50%) and product-by-process (claim 9). Stepwise coupling efficiencies and photo-deprotection yields were known to be imperfect; a challenger must establish a reasonable expectation of achieving ≥50% purity for the claimed oligomer lengths, and claim 9's light-directed process steps require the Combination 2/3 chemistry with its attendant priority caveats.
4. Priority/support issue (D.3). If claims 1–10 are fully supported by the June 7, 1989 parent, the strongest third-party art (Southern Genomics 1992; Khrapko 1991; WO 89/10977) may be unavailable or weakened by date, and the same-inventor disclosures cannot serve as § 103 references. If any claim limitation is new matter relative to the 1989 parent, the Fodor Science paper and WO 90/15070 become powerful § 102(b)-dated references for a § 103 ground. This is the pivotal question, and the materials in hand do not resolve it — it requires a written-description/support analysis of the parent chain (07/362,901 → 07/492,462/'854 → 07/850,356/'783 → 07/954,646/'934).
5. Secondary considerations. The record (not developed here) would include the commercial success of Affymetrix's GeneChip products and long-felt need for high-throughput sequencing; conversely, near-simultaneous independent development by Southern, Khrapko, and others can support a finding of obviousness. Note the patent expired in 2012, so the analysis is of historical/technical interest and potentially relevant to damages windows or reissue-type questions, not to current enforceability.

---

H. Bottom line

On the record available to me — and setting aside the unresolved priority/support question — the strongest § 103 case against claims 1–8 and 10 is Combination 1: sequencing-by-hybridization literature (Bains & Smith 1988; Drmanac 1989; Southern WO 89/10977) requiring complete sets of >10³ known-sequence oligonucleotides at known addresses, implemented with routine covalent solid-phase phosphoramidite synthesis and conventional arraying/patterning, with the <1 cm² footprint justified by routine photolithographic scaling (Sze/Mead). The strongest case against the light-directed product-by-process claim 9 is **Combinations 2/3**, but those grounds depend on same-inventor disclosures and on the priority-date analysis, and should be pleaded only after a written-description/support audit of the parent chain. Claims 2–4 (density escalation) and 10 (>10⁴) follow from the same combinations as predictable scale-ups; claim 5 (purity) and claim 6 (linker) map onto standard chemistry but require case-specific yield/expectation evidence.

Confidence statement: High confidence in the legal framework, claim structure, and the existence and thrust of the SBH and VLSIPS art described. Medium-to-low confidence on (i) the exact content of references I could not open in full (WO 89/10977; Khrapko; Southern Genomics 1992), (ii) the missing [56] examiner-cited list, and (iii) the priority/support analysis, which is dispositive and cannot be completed from the materials provided. These items should be verified against USPTO Patent Center, Espacenet ("Documents cités"), and the file wrapper before the analysis is relied upon.